Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Adcytherix logo — Building an ADC Powerhouse

Adcytherix

Building an ADC Powerhouse

Founded 2024 France France 24 employees Series A Total: $135.00M

General Information

Company Name Adcytherix
Founded Year 2024
Location France France
Employees 24
Funding Stage Series A
Business Model B2B
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Adcytherix. To contact Adcytherix, visit adcytherix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Adcytherix compare?

A PDF of Adcytherix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Adcytherix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Adcytherix

Adcytherix, poised as a biopharmaceutical innovator, is trailblazing advancements in the antibody-drug conjugate (ADC) sector, particularly targeting challenging conditions like cancer. Established in 2024 in France, the company benefits from a seasoned leadership team initiated by Jack Elands, along with Pontifax Venture Capital executives Xavier Preville and Carsten Dehning.

Adcytherix’s strategic focus lies in leveraging its expert-backed framework to create novel ADC therapies, addressing high unmet medical demands. Their vision as an "ADC Powerhouse" resonates through the strong intellectual and operational backbone, contributed by globally acknowledged specialists in ADC development.

In a significant capital boost on 01 October 2025, Adcytherix secured a €105.00M Series A investment from prominent entities including Bpifrance, Kurma Partners, Pontifax, RA Capital Management, and more, underpinning investor confidence in its innovative trajectory and potential market impact.

Business keywords: biopharmaceutical, antibody-drug conjugates, ADC development, cancer treatment, novel therapeutics, oncology, high unmet need diseases, pharmaceutical innovation, drug development, clinical research, precision medicine, therapeutics development, venture capital-backed

Services & Products

Development of next-generation Antibody-Drug Conjugates
Clinical trial execution and strategy
Collaborations in ADC payload chemistry

Target Customers

Biopharmaceutical companies Oncology healthcare providers Patients with high unmet need cancers Research institutions focused on cancer therapy

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €105.00M 10
Bpifrance Kurma Partners Pontifax
Bpifrance, Kurma Partners +8
01 Oct 2025
Seed €30.00M 4
Pontifax RA Capital Management BB Pureos Bioventures
Pontifax, RA Capital Management +2
01 Jun 2024

Adcytherix Alternatives & Competitors

View All Alternatives
Adcytherix vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
Adcytherix vs
RemeGen荣昌生物
RemeGen荣昌生物 China

用科学提高生命质量

Post IPO
35 employees
Adcytherix vs
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc. United States

Addressing urgent unmet medical needs through deeper science, true originality, and rich experience....

Series B
69 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Adcytherix

Building an ADC Powerhouse
Adcytherix was founded in 2024.
Adcytherix is headquartered in France.
Adcytherix has a B2B business model. Its revenue comes from Licensing and Product Sales.
Adcytherix has approximately 24 employees.
Adcytherix has completed 2 funding rounds, raising a total of $135.00M. The latest funding stage is Series A.
Adcytherix offers: Development of next-generation Antibody-Drug Conjugates, Clinical trial execution and strategy, Collaborations in ADC payload chemistry.
Top alternatives and competitors to Adcytherix include Antharis Therapeutics, Inc., RemeGen荣昌生物, BlossomHill Therapeutics, Inc., TORL BioTherapeutics LLC, Signet Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Adcytherix and Antharis Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Adcytherix, https://bouncewatch.com/company/adcytherix, updated 18 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes